Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Journal of Virology

• Publication date

  1991-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/jvi.65.7.3821-3828.1991PMID 1710291PMCID PMC241413
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pillars Article: The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens

  2005cited by this paper
• The pathogenesis of Burkitt's lymphoma.

  1990cited by this paper
• A cell culture model for T lymphocyte clonal anergy.

  1990cited by this paper
• Antigen recognition by class I-restricted T lymphocytes.

  1989cited by this paper
• Study on the immunogenicity of human class-II-restricted T-cell epitopes: processing constraints, degenerate binding, and promiscuous recognition.

  1989cited by this paper
• Vero cell‐expressed Epstein‐Barr virus (EBV) gp350/220 protects marmosets from EBV challenge

  1989cited by this paper
• HLA-DR and -DQ epitopes and monoclonal antibody specificity.

  1989influential reference
• Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins

  1989cited by this paper
• Validation of a first‐generation epstein‐barr virus vaccine preparation suitable for human use

  1989cited by this paper
• A sequence pattern common to T cell epitopes.

  1988cited by this paper
• The T cell response to the malaria circumsporozoite protein: an immunological approach to vaccine development.

  1988cited by this paper
• Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes

  1988influential reference
• Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans

  1988cited by this paper
• A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules

  1988cited by this paper
• In vitro T cell responses to a candidate Epstein‐Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340

  1988cited by this paper
• A primate species with limited major histocompatibility complex class I polymorphism.

  1988cited by this paper
• Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine.

  1988cited by this paper
• Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography.

  1988cited by this paper
• Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes.

  1988cited by this paper
• Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site

  1987cited by this paper
• Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells

  1987cited by this paper
• Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor.

  1987cited by this paper
• Epitope mapping of the major Epstein-Barr virus outer envelope glycoprotein gp350/220.

  1987cited by this paper
• Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants

  1987cited by this paper
• Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d

  1987cited by this paper
• Differences in antigen presentation to MHC class I-and class II- restricted influenza virus-specific cytolytic T lymphocyte clones

  1986cited by this paper
• Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals.

  1986cited by this paper
• T-cell antigenic sites tend to be amphipathic structures.

  1985cited by this paper
• Binding of immunogenic peptides to Ia histocompatibility molecules

  1985cited by this paper
• T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex.

  1985cited by this paper
• Individual tumors of multifocal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones.

  1985cited by this paper
• Seroepidemiological studies on nasopharyngeal carcinoma in China.

  1985cited by this paper
• Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene

  1985cited by this paper
• Immortalized B lymphocytes produce B-cell growth factor

  1984cited by this paper
• Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus

  1984cited by this paper
• Transcription and DNA sequence of the BamHI L fragment of B95‐8 Epstein‐Barr virus.

  1984cited by this paper
• Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin

  1983cited by this paper
• Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo

  1982cited by this paper
• Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin

  1982cited by this paper
• Epstein-Barr virus antigens-a challenge to modern biochemistry.

  1982cited by this paper
• Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells.

  1981cited by this paper
• The Virus as the Etiologic Agent of Infectious Mononucleosis

  1979cited by this paper
• Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus

  1976cited by this paper
• Epstein-Barr virus--is it time to develop a vaccine program?

  1976cited by this paper
• Standards for total serum protein assays--a collaborative study.

  1975cited by this paper

• Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice

  2024cites this paper
• The Status and Prospects of Epstein–Barr Virus Prophylactic Vaccine Development

  2021cites this paper
• Cytotoxic CD4+ T-cells specific for EBV capsid antigen BORF1 are maintained in long-term latently infected healthy donors

  2021cites this paper
• Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction

  2021cites this paper
• A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection

  2020cites this paper
• Prophylactic and therapeutic strategies for Epstein–Barr virus-associated diseases: emerging strategies for clinical development

  2019cites this paper
• Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities

  2017cites this paper
• Identification of GLA/SE as an effective adjuvant for the induction of robust humoral and cell-mediated immune responses to EBV-gp350 in mice and rabbits.

  2016cites this paper
• The Use of Rabbit Model for the Efficacy of a Novel Epstein-Barr virus (EBV) Peptide Vaccine

  2016influential citation
• Molecular characterisation of Epstein-Barr virus-specific B cell response

  2015cites this paper
• Epstein–barr virus vaccines

  2015cites this paper
• The immunology of Epstein-Barr virus-induced disease.

  2015cites this paper
• EBNA1-specific T cell responses during persistent rhesus LCV infection and the development of a novel therapeutic prototype vaccine for EBV-associated diseases

  2014cites this paper
• Herpesviruses Placating the Unwilling Host: Manipulation of the MHC Class II Antigen Presentation Pathway

  2012cites this paper
• Cycle Recognition Lytic Cycle Antigen Choice and in Lytic Contrast with CD8 Responses in Breadth of T Cell Responses to EBV + Cytotoxic CD4

  2011influential citation
• EBV-gp350 Confers B-Cell Tropism to Tailored Exosomes and Is a Neo-Antigen in Normal and Malignant B Cells—A New Option for the Treatment of B-CLL

  2011cites this paper
• Cytotoxic CD4+ T Cell Responses to EBV Contrast with CD8 Responses in Breadth of Lytic Cycle Antigen Choice and in Lytic Cycle Recognition

  2011influential citation
• Soluble Rhesus Lymphocryptovirus gp350 Protects against Infection and Reduces Viral Loads in Animals that Become Infected with Virus after Challenge

  2011cites this paper
• Diagnostic and Protective Aspects of Humoral Immune Responses to Epstein-Barr Virus Encoded Proteins in Nasopharyngeal Carcinoma

  2010cites this paper
• Prospects of a novel vaccination strategy for human gamma-herpesviruses

  2010cites this paper
• An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link

  2009cites this paper
• The role of regulatory T cells in primary infection with Epstein-Barr virus

  2008cites this paper
• Epstein-Barr virus vaccine development: a lytic and latent protein cocktail.

  2008cites this paper
• Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

  2007cites this paper
• Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins

  2006cites this paper
• Long-Term MHC Class II Presentation of the EBV Lytic Protein BHRF1 by EBV Latently Infected B Cells following Capture of BHRF1 Antigen1

  2005cites this paper
• The human T cell immune response to Epstein-Barr virus.

  2005cites this paper
• Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1.

  2004cites this paper
• Control of viral disease: the development of Epstein-Barr virus vaccines

  2004cites this paper
• The immune response to Epstein-Barr virus.

  2004cites this paper
• Infectious mononucleosis and Epstein-Barr virus

  2004cites this paper
• The Evolution of Antigen-Specific CD8+ T Cell Responses after Natural Primary Infection of Humans with Epstein-Barr Virus

  2003cites this paper
• Cytolytic CD4+-T-Cell Clones Reactive to EBNA1 Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation

  2003cites this paper
• Immune Responses to Epstein-Barr Viral Infection

  2002cites this paper
• Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses

  2001cites this paper
• The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines.

  1999cites this paper
• CD4+ T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis.

  1998cites this paper
• Cloning and analysis of the Epstein-Barr virus glycoprotein 350 genes.

  1998cites this paper
• Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.

  1997cites this paper
• Lymphoblastoid cells transfected with c‐myc: Downregulation of EBV‐lytic antigens and impaired response of autologousCD4+ T cells in vitro

  1996cites this paper
• Cytotoxic T-Lymphocyte Responses During Acute Epstein-Barr Virus Infection

  1996cites this paper
• Immunisation of common marmosets with vaccinia virus expressing Epstein‐Barr virus (EBV) gp340 and challenge with EBV

  1996cites this paper
• Immune regulation in Epstein-Barr virus-associated diseases

  1995cites this paper
• Development of Epstein-Barr Virus Vaccines

  1995cites this paper
• T cell proliferative response to bovine leukaemia virus (BLV): identification of T cell epitopes on the major core protein (p24) in BLV-infected cattle with normal haematological values.

  1994cites this paper
• A pattern search method for putative anchor residues in T cell epitopes

  1993cites this paper
• MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways.

  1993cites this paper
• Conformation-dependent recognition of baculovirus-expressed Epstein-Barr virus gp350 by a panel of monoclonal antibodies.

  1993cites this paper
• Progress in the Development of Epstein-Barr Virus Vaccines

  1993cites this paper
• Elucidation of antigenic epitopes on the rubella virus E1 glycoprotein

  1993cites this paper
• Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin.

  1993cites this paper
• The Epstein-Barr virus candidate vaccine antigen gp340/220 is highly conserved between virus types A and B.

  1993cites this paper
• Distribution of epitopes within the amino acid sequence of the Epstein-Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera.

  1992cites this paper
• Purification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papillomavirus virus expression vector system.

  1992cites this paper
• Epstein-Barr virus vaccines.

  1992cites this paper
• Characterization of the specificity and genetic restriction of human CD4+ cytotoxic T cell clones reactive to capsid antigen of rubella virus

  1992cites this paper
• Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340

  1992cites this paper